Anver Basha Shaik

Anver Basha Shaik

Auto-generated profile, based on publicly available information

Anver Basha Shaik

Chemistry and Synthesis Center, National Heart Lung and Blood Institute

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ABAlessandro Bonifazi
Alessandro Bonifazi
FBFrancisco O. Battiti
Francisco O. Battiti
JSJulie Sanchez
Julie Sanchez
SZSaheem A. Zaidi
Saheem A. Zaidi
EBEric Bow
Eric Bow
ANAmy Hauck Newman
Amy Hauck Newman

12 October 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ASAnver Basha Shaik
Anver Basha Shaik
CBComfort A. Boateng
Comfort A. Boateng
FBFrancisco O. Battiti
Francisco O. Battiti
ABAlessandro Bonifazi
Alessandro Bonifazi
JCJianjing Cao
Jianjing Cao
ANAmy Hauck Newman
Amy Hauck Newman

5 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
XCXuemin Chen
Xuemin Chen
MCMcKenna C. Crawford
McKenna C. Crawford
YXYing Xiong
Ying Xiong
ASAnver Basha Shaik
Anver Basha Shaik
KSKiall F. Suazo
Kiall F. Suazo
JMJordan L. Meier
Jordan L. Meier
The transcriptional coactivators EP300 and CREBBP are critical regulators of gene expression that share high sequence identity but exhibit non-redundant functions in basal and pathological contexts. Here, we report the development of a bifunctional small molecule, MC-1, capable of selectively degrading EP300 over CREBBP. Using a potent aminopyridine-based inhibitor of the EP300/CREBBP catalytic domain in combination with a VHL ligand, we demonstrate that MC-1 preferentially degrades EP300 in a proteasome-dependent manner. Mechanistic studies reveal that selective degradation cannot be predicted solely by target engagement or ternary complex formation, suggesting additional factors govern paralogue-specific degradation. MC-1 inhibits cell proliferation in a subset of cancer cell lines and provides a new tool to investigate the non-catalytic functions of EP300 and CREBBP. Our findings expand the repertoire of EP300/CREBBP-targeting chemical probes and offer insights into the determinants of selective degradation of highly homologous proteins.